2.33
0.03 (1.30%)
Previous Close | 2.30 |
Open | 2.29 |
Volume | 1,273,147 |
Avg. Volume (3M) | 1,492,843 |
Market Cap | 1,609,312,256 |
Price / Earnings (TTM) | 233.00 |
Price / Earnings (Forward) | 135.14 |
Price / Sales | 13.80 |
Price / Book | 19.44 |
52 Weeks Range | |
Earnings Date | 23 Aug 2024 |
Profit Margin | 5.10% |
Operating Margin (TTM) | 1.83% |
Diluted EPS (TTM) | 0.010 |
Quarterly Revenue Growth (YOY) | 54.50% |
Total Debt/Equity (MRQ) | 21.32% |
Current Ratio (MRQ) | 3.41 |
Operating Cash Flow (TTM) | 3.68 M |
Levered Free Cash Flow (TTM) | -1.46 M |
Return on Assets (TTM) | 0.56% |
Return on Equity (TTM) | 7.65% |
Market Trend
Short Term | Medium Term | ||
Industry | Medical Devices (AU) | Mixed | Mixed |
Medical Devices (Global) | Mixed | Mixed | |
Stock | POLYNOVO FPO [PNV] | - | - |
AIStockmoo Score
Analyst Consensus | 0.0 |
Insider Activity | NA |
Price Volatility | 1.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -0.5 |
Average | 0.75 |
Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months. |
|
Sector | Healthcare |
Industry | Medical Devices |
Investment Style | Small Growth |
% Held by Insiders | 11.08% |
% Held by Institutions | 18.60% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |